San Francisco based R-Zero, a biosafety company dedicated to developing the most effective hospital-grade technologies to reduce the spread of infectious disease, raised US$ 15M in Series A funding.
The Series A round of financing was led by DBL Partners, one of the largest pioneering and leading impact investors, with participation from Bedrock Capital and HAX / SOSV. Ira Ehrenpreis, the Managing Partner at DBL Partners, has joined R-Zero’s Board of Directors.
This capital raised will be utilized by R-Zero to further accelerate its production and deployment of its flagship IoT UV-C system to meet strong demand. It will also be put to the development of its new product innovations that will further contribute to a new standard of public health and safety.
Headquartered in San Francisco, CA, R-Zero was founded in the early stages of the pandemic by co-founders Ben Boyer, Grant Morgan and Eli Harris. They recognized a unique opportunity to revolutionize the US$ 20B+ infection prevention industry and help businesses increase employee and customer safety.
The cost of UV-C disinfection technology can range between $60,000 and $125,000 per unit and it has been limited to hospitals. Alternatively, R-Zero’s flagship germicidal UV device, Arc, successfully offers the same or better safety and efficacy as the systems used in hospitals, at a fraction of the price (via hardware-as-a-service subscription).
“In a time when an invisible microorganism is causing unprecedented human suffering and economic destruction on a truly global scale, businesses everywhere need solutions that enable them to reopen doors and keep them open safely. As pathogens have evolved, the tools we use to combat them have not. The need for innovation around how we create safer spaces has never been more urgent and apparent. We see an opportunity to modernize the infection-prevention industry by building upon a proven science and applying intelligent hardware, easy-to-use software, and data science, to restore consumer trust and stop the spread of infectious disease, now and forever,” said Grant Morgan, CEO and Co-founder of R-Zero.
What Investors have to say
“In today’s world, nothing is more important than the health and safety of our families, fellow employees and frontline workers, but unfortunately the cost of effective disinfection protocols has been prohibitively expensive. Through innovation and cost reduction, R-Zero democratizes access to safety for businesses and communities alike. In much the same way as companies in other critical industries have experienced exponential growth by unlocking new technologies and attracting a new breed of entrepreneurial talent, R-Zero is similarly poised to benefit from impact investment dollars. The goal is to modernize the disinfection space with its breakthrough technology, aimed at addressing the critical societal issues around trust, appropriate health protocols, and the need for safer spaces,” said Ira Ehrenpreis, Managing Partner at DBL Partners and R-Zero board member.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!